secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-05-15T12:05:59+00:00
Accession:  0001437749-26-017222
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Q1 net loss $2.3M; PMDA determines CardiAMP safety/efficacy likely sufficient for Japan approval
--------------------------------------------------------------------------------

- Net loss $2.3M in Q1 2026 vs $2.7M in Q1 2025; cash $951k as of March 31, 2026.
- PMDA Formal Clinical Consultation determined clinical safety and efficacy likely sufficient for market clearance; alignment on foreign data.
- FDA expressed no safety concerns, benefits intriguing; confirmed PMA pathway; recommended continuing CardiAMP HF II confirmatory trial.
- FDA agreed on two Helix clearance pathways; milestones: Euro PCR presentation Q2 2026, Japan Shonin submission Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926017222/0001437749-26-017222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926017222/bcda20260515_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer